Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention

• Asıl Yazarlar: Patel V (Yazar), Lin FJ (Yazar), Ojo O (Yazar), Rao S (Yazar), Yu S (Yazar), Zhan L (Yazar), Touchette DR (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Centro de Investigaciones y Publicaciones Farmaceuticas, 2014-09-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background: Prasugrel is recommended over clopidogrel in poor/intermediate CYP2C19 metabolizers with acute coronary syndrome (ACS) and planned percutaneous coronary intervention (PCI), reducing the risk of ischemic events. CYP2C19 genetic testing can guide antiplatelet therapy in ACS patients. Objec...